Browse our anti-MEN1 (MEN1) Antibodies

Full name:
anti-Multiple Endocrine Neoplasia I Antibodies (MEN1)
On www.antibodies-online.com are 108 Multiple Endocrine Neoplasia I (MEN1) Antibodies from 12 different suppliers available. Additionally we are shipping MEN1 Proteins (3) and MEN1 Kits (1) and many more products for this protein. A total of 115 MEN1 products are currently listed.
Synonyms:
AW045611, MEAI, menin, SCG2

Most Popular Reactivities for anti-MEN1 (MEN1) Antibodies

Select your species and application

anti-Mouse (Murine) MEN1 Antibodies:

anti-Human MEN1 Antibodies:

anti-Rat (Rattus) MEN1 Antibodies:

All available anti-MEN1 Antibodies

Go to our pre-filtered search.

Top referenced anti-MEN1 Antibodies

  1. Human Polyclonal MEN1 Primary Antibody for ChIP, ICC - ABIN151584 : Hughes, Rozenblatt-Rosen, Milne, Copeland, Levine, Lee, Hayes, Shanmugam, Bhattacharjee, Biondi, Kay, Hayward, Hess, Meyerson: Menin associates with a trithorax family histone methyltransferase complex and with the hoxc8 locus. in Molecular cell 2004 (PubMed)
    Show all 26 references for 151584

More Antibodies against MEN1 Interaction Partners

Mouse (Murine) Multiple Endocrine Neoplasia I (MEN1) interaction partners

  1. Menin and PRMT5 (show PRMT5 Antibodies) suppress GLP1R (show GLP1R Antibodies) transcript levels and PKA-mediated phosphorylation of FOXO1 (show FOXO1 Antibodies) and CREB (show CREB1 Antibodies).

  2. Inactivation of Kmt2a (show MLL Antibodies) in Men1-deficient mice accelerated pancreatic islet tumorigenesis and shortened the average life span. Increases in cell proliferation were observed in mouse pancreatic islet tumors upon inactivation of both Kmt2a (show MLL Antibodies) and Men1.

  3. Data suggest that menin inhibits differentiation into terminal effectors and positively controls proliferation and survival of Ag-specific CD8 (show CD8A Antibodies)(+) T cells that are activated upon infection; study uncovered an important role for menin in the immune response of CD8 (show CD8A Antibodies)(+) T cells to infection

  4. Our data further confirms that deletion of Men1 alone does not favour carcinoid development, but rather cooperates with additional loci.

  5. Menin binds on the promoter of Inhbb (show INHBB Antibodies) gene where it favours the recruitment of Ezh2 (show EZH2 Antibodies) via an indirect mechanism involving Akt (show AKT1 Antibodies)-phosphorylation.

  6. Results indicate that fasted male Men1(+/-) mice, in the early stage of development of MEN1, display glucose metabolic disorders. These disorders are caused not by direct induction of insulin (show INS Antibodies) resistance, but via increased glucagon (show GCG Antibodies) secretion and the consequent stimulation of hepatic glucose production.

  7. The inactivation of menin in the thyroid gland of young mice does not seem to change the histological pattern, but it influences the proliferation of follicular cells. Further molecular studies especially in aged mice are needed to better understand the correlation between certain oncogenes and the inactive status of menin.

  8. Data show that progranulin (show GRN Antibodies) is upregulated in neuroendocrine tumors (NETs) and islets of the multiple endocrine neoplasia 1 protein (MEN1) mouse as well as in the serum of patients with pancreatic NETs associated with glucagonoma syndrome.

  9. Although mice lacking Men1 developed insulinomas as expected, elimination of ARC (show NOL3 Antibodies) in this context did not significantly alter tumor load. Cellular rates of proliferation and death in these tumors were also not perturbed in the absence of ARC (show NOL3 Antibodies).

  10. The study characterized the binding position of Ezh2 (show EZH2 Antibodies) and menin at all annotated genes in embryonic stem cells and B and T lymphocytes.

Human Multiple Endocrine Neoplasia I (MEN1) interaction partners

  1. knockdown of RPA2 (show RPA2 Antibodies) promoted formation of the menin-p65 (show GORASP1 Antibodies) complex and repressed the expression of NF-kappaB (show NFKB1 Antibodies)-mediated genes. RPA2 (show RPA2 Antibodies) expression was induced via an E2F1 (show E2F1 Antibodies)-dependent mechanism in MCF7 and MDA-MB-231 cells treated with NF-kappaB (show NFKB1 Antibodies) activators, TNF-alpha (show TNF Antibodies) or lipopolysaccharide (LPS (show IRF6 Antibodies)).

  2. Loss of Menin is an early event in pancreatic neuroendocrine tumorigenesis and that ATRX (show ATRX Antibodies)/DAXX (show DAXX Antibodies) loss and alternative lengthening of telomeres are relatively late events.

  3. The lack of somatic CDKN1B (show CDKN1B Antibodies) mutations in our samples points to a rare involvement in parathyroid adenomas, despite the frequent loss of nuclear p27 (show PAK2 Antibodies) expression. MEN1 biallelic inactivation seems to be directly related to down-regulation of p27 (show PAK2 Antibodies) expression through the inhibition of CDKN1B (show CDKN1B Antibodies) gene transcription.

  4. This result shows a novel mechanism whereby menin, a RNA-binding protein, facilitates the processing of its specific miRNA by regulating the dynamics of the menin-miR-24 Gene Regulatory Network at the level of pri-miRNA processing.

  5. findings reveal a previously unappreciated cross-talk between two crucial tumor suppressor genes, MEN1 and DAXX (show DAXX Antibodies), thought to work by independent pathways

  6. Multiple endocrine neoplasia type 1-related primary hyperparathyroidism patients experienced more common kidney complications but less skeletal issues, and a milder biochemical manifestation compared with SHPT patients. MEN1 mutation detection rate was 79.4% and 9 of the identified mutations were novel.

  7. miR (show MLXIP Antibodies)-24-dependent expression of menin may be important in the regulation of nonmalignant and cholangiocarcinoma proliferation.

  8. rs2959656, a nonsynonymous variant in MEN1, is associated with the development of clinically active pituitary adenoma.

  9. Study acts as a further supplement of the genetic features of neuroendocrine tumors. Somatic mutations of three potential tumor-related genes (HRAS (show HRAS Antibodies), PAK1 (show PAK1 Antibodies) and MEN1) might contribute to the tumorigenesis of thymic neuroendocrine tumors with EAS.

  10. The results and clinical course of disease in this case indicate the potential role of menin in the development of non-endocrine or atypical-endocrine tumors in MEN1 patients.

MEN1 Antigen Profile

Antigen Summary

This gene encodes menin, a putative tumor suppressor associated with a syndrome known as multiple endocrine neoplasia type 1. In vitro studies have shown menin is localized to the nucleus, possesses two functional nuclear localization signals, and inhibits transcriptional activation by JunD, however, the function of this protein is not known. Two messages have been detected on northern blots but the larger message has not been characterized. Alternative splicing results in multiple transcript variants.

Alternative names and synonyms associated with MEN1

  • multiple endocrine neoplasia I (men1) antibody
  • multiple endocrine neoplasia I (MEN1) antibody
  • multiple endocrine neoplasia 1 (Men1) antibody
  • multiple endocrine neoplasia I (Men1) antibody
  • AW045611 antibody
  • MEAI antibody
  • menin antibody
  • SCG2 antibody

Protein level used designations for MEN1

multiple endocrine neoplasia 1 , menin , multiple endocrine neoplasia I , menin-like , multiple endocrine neoplasia protein

GENE ID SPECIES
549115 Xenopus (Silurana) tropicalis
692344 Felis catus
743979 Pan troglodytes
100158320 Xenopus laevis
100411101 Callithrix jacchus
100441476 Pongo abelii
100472417 Ailuropoda melanoleuca
100538227 Danio rerio
17283 Mus musculus
4221 Homo sapiens
29417 Rattus norvegicus
483758 Canis lupus familiaris
100523533 Sus scrofa
539431 Bos taurus
Selected quality suppliers for anti-MEN1 (MEN1) Antibodies
Did you look for something else?